Table 1.
Baseline characteristics
| Characteristics | Premenopausal | Postmenopausal | ||
|---|---|---|---|---|
| Exercise (n = 107) | Control (n = 94) | Exercise (n = 128) | Control (n = 115) | |
| Age, years* (range) | 46.0 (36.0–54.3) | 46.2 (34.7–56.6) | 57.4 (47.2–67.6) | 58.0 (45.7–68.2) |
| Tumor size, mm** (range) | 18 (5–70) | 20 (4–72) | 18 (4–100) | 20 (4–130) |
| Metastatic lymph nodes, n** (range) | 1 (0–17) | 1 (0–42) | 1 (0–20) | 1 (0–17) |
| Weight, kg* (SD) | 69.5 (10.5) | 69.6 (12.6) | 73.1 (12.4) | 69.5 (12.0) |
| Height, cm* (SD) | 165.8 (6.1) | 166.6 (6.3) | 163.6 (5.0) | 163.9 (5.7) |
| BMI, kg/m2* (SD) | 25.3 (3.7) | 25.1 (4.5) | 27.3 (4.3) | 25.9 (4.2) |
| Helsinki population (n = 346) | ||||
| FN aBMD, g/cm2* (SD) | 0.77 (0.08) | 0.79 (0.11) | 0.77 (0.11) | 0.77 (0.11) |
| TH aBMD, g/cm2* (SD) | 0.90 (0.01) | 0.94 (0.01) | 0.93 (0.01) | 0.93 (0.01) |
| LS aBMD, g/cm2* (SD) | 0.98 (0.10) | 1.01 (0.12) | 0.98 (0.11) | 0.98 (0.11) |
| Tampere population (n = 65) | ||||
| FN aBMD, g/cm2* (SD) | 0.94 (0.08) | 0.96 (0.07) | 0.95 (0.15) | 0.92 (0.12) |
| TH aBMD, g/cm2* (SD) | 1.01 (0.03) | 1.03 (0.02) | 1.02 (0.04) | 0.99 (0.03) |
| LS aBMD, g/cm2* (SD) | 1.15 (0.13) | 1.15 (0.13) | 1.14 (0.18) | 1.11 (0.12) |
| Turku population (n = 32) | ||||
| FN aBMD, g/cm2* (SD) | 0.78 (0.08) | 0.85 (0.16) | 0.77 (0.12) | 0.80 (0.09) |
| TH aBMD, g/cm2* (SD) | 0.91 (0.03) | 0.98 (0.09) | 0.87 (0.04) | 0.91 (0.04) |
| LS aBMD, g/cm2* (SD) | 0.97 (0.11) | 1.13 (0.20) | 0.97 (0.09) | 0.93 (0.09) |
| Leisure time activity, n (%) | ||||
| Low | 19 (17.8) | 14 (14.9) | 25 (19.5) | 15 (13.0) |
| Moderate | 53 (49.5) | 50 (53.2) | 68 (53.1) | 68 (59.1) |
| High | 32 (29.9) | 23 (24.5) | 31 (24.2) | 28 (24.3) |
| Missing data | 3 (2.8) | 7 (7.4) | 4 (3.2) | 4 (3.6) |
| MET-h/week* (SD) | 26.4 (14.6) | 26.1 (15.0) | 27.0 (18.3) | 26.9 (17.7) |
| Radiotherapy, n (%) | 85 (79.4) | 67 (71.3) | 99 (77.3) | 94 (81.7) |
| Chemotherapy, n (%) | 96 (89.7) | 86 (91.5) | 113 (88.3) | 106 (92.2) |
| Endocrine therapy, n (%) | ||||
| Tamoxifen | 89 (83.2) | 68 (72.3) | 38 (29.7) | 33 (28.7) |
| Aromatase inhibitor | 2 (1.9) | 2 (2.1) | 67 (52.3) | 65 (56.5) |
| Other therapy or missing data | 16 (15.0) | 24 (25.6) | 23 (17.9) | 17 (14.8) |
* mean, ** median, n number, SD standard deviation, BMI body mass index, aBMD areal bone mineral density